Islet-cell antibodies and type 1 diabetes after treatment with interferon-alpha;Autoantikörper gegen inselzellantigene und diabetes mellitus typ 1 unter interferon alpha-kombinationstherapie

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 20, 2004, Pages 1120-1124

  Schories, M ^a   Peters, T ^b   Rasenack, J ^a   Reincke, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Innere Medizin II ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; AUTOANTIBODY; CARBOXYLASE; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; PLACEBO; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; ANTIVIRUS AGENT;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MONOTHERAPY; PROSPECTIVE STUDY; RANDOMIZATION; TREATMENT FAILURE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; PANCREAS ISLET; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AMANTADINE; ANTIVIRAL AGENTS; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT FAILURE;

EID: 2942529420     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-824859     Document Type: Article

References (36)

1. Ando H, Nagai Y, Yokoyama M, Takamura T, Kobayashi K. Antibodies to GAD in diabetic patients with chronic hepatitis C. Diabet Med 1998; 15: 797
2. Betterle C, Fabris P, Zanchetta R et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 1177-1181
3. Bhatti A, McGarrity TJ, Gabbay R. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C. Am J Gastroenterol 2001; 96: 604-605
4. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med 2001; 18: 329-332
5. Di Cesare E, Previti M, Russo F et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci 1996; 41: 1672-1677
6. Durand JM. Extrahepatic manifestations of hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1402
7. Eibl N, Gschwantler M, Ferenci P, Eibl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol 2001; 13: 295-298
8. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439-1445
9. El-Zayadi AR, Selim OE, Hamdy H, Dabbous H, Ahdy A, Moniem SA. Association of chronic hepatitis C infection and diabetes mellitus. Trop Gastroenterol 1998; 19: 141-144
10. Fabris P, Betterle C, Floreani A et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548
11. Fabris P, Betterle C, Greggio NA et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514-517
12. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549-558
13. Ferri C, Zignego AL. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 2000; 12: 53-60
14. Floreani A, Chiaramonte M, Greggio NA et al. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital J Gastroenterol Hepatol 1998; 30: 71-76
15. Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 604-605
16. Hadziyannis SJ. Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci 1996; 41: 63S-74S(Suppl 12
17. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997; 4: 9-28
18. Harman-Boehm I, Zingman L, Hilzenrat N. No evidence for anti-islet autoimmunity in diabetes mellitus associated with chronic hepatitis C infection. Hepatology 1999; 30: 342
19. Hieronimus S, Fredenrich A, Tran A, Benzaken S, Fenichel P. Antibodies to GAD in chronic hepatitis C patients. Diabetes Care 1997; 20: 1044
20. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med 1998; 4: 231-239
21. Imagawa A, Itoh N, Hanafusa T et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995; 80: 922-926
22. Kado S, Miyamoto J, Komatsu N et al. Type 1 diabetes mellitus caused by treatment with interferon-beta. Intern Med 2000; 39: 146-149
23. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003; 325: 135-148
24. Mofredj A, Howaizi M, Grasset D et al. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002; 47: 1649-1654
25. Narvaez I, Perez B, del Mar Alcalde M, Jimenez C, Soria A. Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease. Am J Gastroenterol 2003; 98: 2336-2337
26. Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J Autoimmun 2001; 16: 275-285
27. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291
28. Paris R. Association of hepatitis C and diabetes mellitus. Ann Intern Med 2001; 135: 141-142
29. Piquer S, Hernandez C, Enriquez J et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 2001; 137: 38-42
30. Recasens M, Aguilera E, Ampurdanes S et al. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 2001; 18: 764-767
31. Seifarth C, Benninger J, Bohm BO, Wiest-Ladenburger U, Hahn EG, Hensen J. Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C. Z Gastroenterol 1999; 37: 235-239
32. Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I. Interferon-alpha and development of type 1 diabetes: a case without insulin resistance. Diabetes Care 1998; 21: 1774
33. Uto H, Matsuoka H, Murata M et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 2000; 49: 101-106
34. Wasmuth HE, Stolte C, Geier A, Gartung C, Matern S. Induction of multiple autoantibodies to islet cell antigens during treatment with interferon alpha for chronic hepatitis C. Gut 2001; 49: 596-597
35. Wesche B, Jaeckel E, Trautwein C et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001; 48: 378-383
36. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002; 56: 793-798